تقرير
Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy.
| العنوان: | Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy. |
|---|---|
| المؤلفون: | Zhong K; Department of Hepatobiliary Surgery II, General Surgery Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China., Xu Y; Department of Hepatobiliary Surgery II, General Surgery Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China., Cheng Y; Department of Hepatobiliary Surgery II, General Surgery Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China., Wen Y; Department of Hepatobiliary Surgery II, General Surgery Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China., Cai L; Department of Hepatobiliary Surgery II, General Surgery Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China., He G; Department of Hepatobiliary Surgery II, General Surgery Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China., Huang H; Department of Hepatobiliary Surgery II, General Surgery Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China., Fu S; Department of Hepatobiliary Surgery II, General Surgery Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China., Zhong X; The Medical Department, 3D Medicines, Inc., Shanghai, China., Zheng Y; The Medical Department, 3D Medicines, Inc., Shanghai, China., Chen T; The Medical Department, 3D Medicines, Inc., Shanghai, China., Huang M; The Medical Department, 3D Medicines, Inc., Shanghai, China., Pan M; Department of Hepatobiliary Surgery II, General Surgery Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China. |
| المصدر: | Frontiers in immunology [Front Immunol] 2022 Aug 31; Vol. 13, pp. 999763. Date of Electronic Publication: 2022 Aug 31 (Print Publication: 2022). |
| نوع المنشور: | Case Reports; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Carcinoma, Hepatocellular*/complications , Carcinoma, Hepatocellular*/pathology , Carcinoma, Hepatocellular*/therapy , Liver Neoplasms*/complications , Liver Neoplasms*/pathology , Liver Neoplasms*/therapy , Thrombosis*/pathology, Humans ; Immunotherapy ; Middle Aged ; Portal Vein/pathology ; Sorafenib/therapeutic use ; Tumor Microenvironment |
| مستخلص: | Portal vein tumor thrombus (PVTT) is a frequent complication in hepatocellular carcinoma (HCC). HCC patients with PVTT have the characteristics of less treatment tolerance and poor prognosis. Immunotherapy, especially combined immunotherapy, has been successfully used in advanced HCC. However, there are no recognized universally indicators that can predict response or resistance to immunotherapy for HCC. Herein, we reported a 58-year-old HCC patient with PVTT, cirrhosis and chronic viral hepatitis, who achieved complete response (CR) after combined immunotherapy (camrelizumab combined with sorafenib or regorafenib), according to his high enrichment of tumor-infiltrating immune cells and tertiary lymphoid structure (TLS). In this case, we revealed the characteristics of the baseline tumor immune microenvironment (TIME) in a HCC patient who responded well to combined immunotherapy, suggesting that TIME can be used to assist in clinical decision making of immunotherapy for HCC. Competing Interests: Authors XZ, YZ, TC, and MH were employed by 3D Medicines, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Zhong, Xu, Cheng, Wen, Cai, He, Huang, Fu, Zhong, Zheng, Chen, Huang and Pan.) |
| References: | Semin Liver Dis. 2018 Aug;38(3):242-251. (PMID: 30041276) Nat Rev Clin Oncol. 2018 Oct;15(10):599-616. (PMID: 30061739) Int J Surg. 2015 Aug;20:8-16. (PMID: 26026424) Nature. 2020 Jan;577(7791):549-555. (PMID: 31942075) Nature. 2020 Jan;577(7791):556-560. (PMID: 31942077) Cell. 2018 Oct 4;175(2):313-326. (PMID: 30290139) Nat Med. 2018 May;24(5):541-550. (PMID: 29686425) Gut. 2021 Jan;70(1):204-214. (PMID: 32747413) N Engl J Med. 2020 May 14;382(20):1894-1905. (PMID: 32402160) Nature. 2020 Jan;577(7791):561-565. (PMID: 31942071) J Hepatol. 2012 Oct;57(4):821-9. (PMID: 22727733) Clin Cancer Res. 2022 Aug 15;28(16):3499-3508. (PMID: 35275208) Ann Surg Oncol. 2014 Jun;21(6):1825-33. (PMID: 24499831) Clin Cancer Res. 2021 Feb 15;27(4):1003-1011. (PMID: 33087333) J Hepatol. 2016 Nov;65(5):938-943. (PMID: 27266618) J Hepatol. 2020 Dec;73(6):1460-1469. (PMID: 32710922) Lancet. 2017 Jan 7;389(10064):56-66. (PMID: 27932229) Front Immunol. 2021 May 26;12:648812. (PMID: 34122408) |
| فهرسة مساهمة: | Keywords: combined immunotherapy; hepatocellular carcinoma (HCC); portal vein tumor thrombus (PVTT); tertiary lymphoid structure (TLS); tumor immune microenvironment (TIME) |
| المشرفين على المادة: | 9ZOQ3TZI87 (Sorafenib) |
| تواريخ الأحداث: | Date Created: 20220919 Date Completed: 20220920 Latest Revision: 20220924 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9471014 |
| DOI: | 10.3389/fimmu.2022.999763 |
| PMID: | 36119069 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2022.999763 |